These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 29897231)
1. Correction to Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses. Zhou ZZ; Cheng YF; Zou ZQ; Ge BC; Yu H; Huang C; Wang HT; Yang XM; Xu JP ACS Chem Neurosci; 2018 Jul; 9(7):1868. PubMed ID: 29897231 [No Abstract] [Full Text] [Related]
2. Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses. Zhou ZZ; Cheng YF; Zou ZQ; Ge BC; Yu H; Huang C; Wang HT; Yang XM; Xu JP ACS Chem Neurosci; 2017 Jan; 8(1):135-146. PubMed ID: 27690383 [TBL] [Abstract][Full Text] [Related]
3. Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings. Zhou ZZ; Ge BC; Zhong QP; Huang C; Cheng YF; Yang XM; Wang HT; Xu JP Eur J Med Chem; 2016 Nov; 124():372-379. PubMed ID: 27597413 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways. Yu H; Zou Z; Zhang X; Peng W; Chen C; Ye Y; Xu J; Wang H Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29419799 [TBL] [Abstract][Full Text] [Related]
5. FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress. Zhong Q; Yu H; Huang C; Zhong J; Wang H; Xu J; Cheng Y Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():62-75. PubMed ID: 30391306 [TBL] [Abstract][Full Text] [Related]
6. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses. Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595 [TBL] [Abstract][Full Text] [Related]
7. Chlorbipram: a novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer. Zhang MZ; Zhou ZZ; Yuan X; Cheng YF; Bi BT; Gong MF; Chen YP; Xu JP Eur J Pharmacol; 2013 Dec; 721(1-3):56-63. PubMed ID: 24113523 [TBL] [Abstract][Full Text] [Related]
8. Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors. Kawasaki M; Fusano A; Nigo T; Nakamura S; Ito MN; Teranishi Y; Matsumoto S; Toda H; Nomura N; Sumiyoshi T Bioorg Med Chem Lett; 2014 Jun; 24(12):2689-92. PubMed ID: 24794103 [TBL] [Abstract][Full Text] [Related]
9. Assessing the emetic potential of PDE4 inhibitors in rats. Robichaud A; Savoie C; Stamatiou PB; Lachance N; Jolicoeur P; Rasori R; Chan CC Br J Pharmacol; 2002 Jan; 135(1):113-8. PubMed ID: 11786486 [TBL] [Abstract][Full Text] [Related]
10. Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain. Hirose R; Manabe H; Nonaka H; Yanagawa K; Akuta K; Sato S; Ohshima E; Ichimura M Eur J Pharmacol; 2007 Nov; 573(1-3):93-9. PubMed ID: 17658510 [TBL] [Abstract][Full Text] [Related]
12. Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression. Liebenberg N; Harvey BH; Brand L; Brink CB Behav Pharmacol; 2010 Sep; 21(5-6):540-7. PubMed ID: 20555254 [TBL] [Abstract][Full Text] [Related]
13. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats. Zhang HT; Zhao Y; Huang Y; Deng C; Hopper AT; De Vivo M; Rose GM; O'Donnell JM Psychopharmacology (Berl); 2006 Jun; 186(2):209-17. PubMed ID: 16586089 [TBL] [Abstract][Full Text] [Related]
14. Novel Phosphodiesterase 4 Inhibitor FCPR03 Alleviates Lipopolysaccharide-Induced Neuroinflammation by Regulation of the cAMP/PKA/CREB Signaling Pathway and NF- Zou ZQ; Chen JJ; Feng HF; Cheng YF; Wang HT; Zhou ZZ; Guo HB; Zheng W; Xu JP J Pharmacol Exp Ther; 2017 Jul; 362(1):67-77. PubMed ID: 28450469 [TBL] [Abstract][Full Text] [Related]
15. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928 [TBL] [Abstract][Full Text] [Related]